HLS Therapeutics Inc. has seen a decline in its stock price this week amid mixed news and low trading volume.
HLS Therapeutics Inc. (HLS.TO) has had a tough week, with its stock price dropping 3.72%. The latest close was C$4.25, reflecting a 2.13% decrease from the previous day. Despite some recent developments in the company, the stock hasn’t attracted much market attention.
Investor takeaway: Investors should pay attention to recent performance trends and company updates, especially the approval of NILEMDO® in Canada and the recent Q1 earnings report, as these could impact future stock performance.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$132.29M
52W high
$5.76
52W low
$4.00
1W change
-3.72%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 77.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.33
+77.0% Upside
Current Price
C$4.14
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.5%
Annualized
90-Day Vol
22.5%
Annualized
Trend (90d)
-48.8%
Annualized drift
90d Mean
C$3.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.91 | C$3.53 – C$4.32 |
| 60 trading days | C$3.69 | C$3.19 – C$4.26 |
| 90 trading days | C$3.48 | C$2.92 – C$4.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc. Hits C$4.25, Down 3.72% This Week
With a market cap of about C$132 million, HLS Therapeutics continues to struggle with profitability, shown by a negative profit margin of 18.5%.
Bull case
The approval of NILEMDO® for reducing LDL cholesterol is a significant addition to HLS Therapeutics' product lineup. This could lead to revenue growth in the upcoming quarters.
Bear case
The stock's decline, along with low trading volume and negative profit margins, raises concerns about the company's ability to attract investor interest and maintain momentum in the market.
Recent Price Action
HLS Therapeutics Inc. closed at C$4.25 on Wednesday, down 2.13% for the day and 3.72% over the week. The stock has faced downward pressure, contributing to a year-to-date decline of 14.64%. This recent price action shows a lack of momentum, with limited trading activity.
Company Developments
Despite the stock's struggles, HLS Therapeutics has made progress in its operations. The company recently reported Q1 earnings of $12.9 million, a 2% increase year-over-year. Additionally, HLS received Health Canada approval for NILEMDO®, which could strengthen its product portfolio in the competitive healthcare market. However, these advancements have not yet sparked significant investor interest.
Technical Picture
The technical indicators for HLS Therapeutics show a current price of C$4.25, below the 50-day moving average of C$4.47 and the 200-day moving average of C$4.75, indicating bearish momentum. The stock has a 52-week range of C$4.00 to C$5.76, with only 14% of this range utilized. The low trading volume of 100 shares compared to the 20-day average of 30,479 shares suggests a lack of market interest.
Insider Activity
There have been no significant insider transactions reported recently for HLS Therapeutics, indicating that insiders may not be actively buying or selling shares at this time.
Price Action Summary
As of the last close, HLS Therapeutics Inc. is trading at C$4.25, down 2.13% for the day. Investors should keep an eye on upcoming developments and market conditions that could influence the stock's trajectory.
Advertisement
